Orforglipron

Orforglipron is an oral GLP-1 receptor agonist manufactured by Eli Lilly, initially prescribed for type 2 diabetes. It's newsworthy due to recent clinical trial results indicating its effectiveness in weight loss, potentially offering a non-injection alternative to drugs like Wegovy and Mounjaro. The FDA has approved a similar oral medication from Eli Lilly, making it the second oral obesity treatment on the market. This development is significant because oral medications are generally more convenient and may be cheaper than injectable options, potentially increasing accessibility. However, experts warn that the availability of oral weight-loss medications could lead to an increase in counterfeit drugs, necessitating stronger regulation and enforcement to protect consumers.